HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, ...

HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced FDA ...

Generally the result of age- related decreases in androgen production, sebaceous hyperplasia is characterized by common asymptomatic papules. The condition occurs most frequently in healthy ...

This patient had sebaceous hyperplasia, a benign proliferation of the sebaceous gland that occurs in a periorbital location on patients of middle age or older. The condition is characterized by small, ...

In October 2020, Pulse initiated its investigational device exemption (“IDE”) study to evaluate the treatment of sebaceous hyperplasia lesions using the CellFX System. On February 8, 2022, before the ...

(RTTNews) - Pulse Biosciences, Inc. (PLSE), a bioelectric medicine company, has received FDA clearance for its CellFX System to expand the indication for use in the treatment of sebaceous hyperplasia ...

Please provide your email address to receive an email when new articles are posted on . Pulse Biosciences has announced it received FDA 510(k) clearance for expanding the use of its CellFX System to ...